Plain-English translation of NCT06297590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study of , a new medication designed to target changes in the brain associated with Alzheimer's disease. Researchers will give participants either the medication or a placebo (inactive treatment) through injections into the spinal fluid, and then carefully monitor safety and how well the medication works.
Current Alzheimer's treatments have limited effectiveness, and researchers believe delivering medication directly into the spinal fluid may help reach the brain more effectively and slow disease progression in people with early symptoms.
You likely qualify if…
You likely don't qualify if…
Participants will receive either the medication or a placebo injected into their spinal fluid through a lumbar puncture (a needle in the lower spine). In Part A, you'll receive one injection and be monitored for about 45 weeks; in Part B, you'll receive two injections over about 100 weeks total. You'll have regular visits for safety checks, blood tests, brain scans, and memory assessments, and a study partner will need to attend appointments with you.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States